Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data

BACKGROUND: In Poland, treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has become available free of charge in a therapeutic program. Assessed herein, is the efficacy and safety of alirocumab and evolocumab in patients with heterozygous familial hypercholesterolemia (F...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Krzysztof Chlebus, Barbara Cybulska, Piotr Dobrowolski, Marzena Romanowska-Kocejko, Marta Żarczyńska-Buchowiecka, Natasza Gilis-Malinowska, Aneta Stróżyk, Justyna Borowiec-Wolna, Marcin Pajkowski, Beata Bobrowska, Renata Rajtar-Salwa, Aleksandra Kwapiszewska, Małgorzata Waluś-Miarka, Magdalena Chmara, Rafał Gałąska, Maciej Małecki, Tomasz Zdrojewski, Marcin Gruchała
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Via Medica 2022-02-01
Edice:	Cardiology Journal
Témata:	familial hypercholesterolemia PCSK9 inhibitors alirocumab evolocumab LDL-cholesterol reduction clinical side effects
On-line přístup:	https://journals.viamedica.pl/cardiology_journal/article/view/86348
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!